Apadamtase alfa, sold under the brand name Adzynma, is an enzyme replacement therapy used to treat thrombotic thrombocytopenic purpura. It is a human recombinant a disintegrin and metalloproteinase with thrombospondin motifs 13, and it is given by injection into a vein. The most common side effects are headache, diarrhea, migraine, abdominal pain, nausea, upper respiratory tract infection, dizziness and vomiting. It was approved for medical use in the United States in November 2023 and in the European Union in August 2024.
Facts
Classification
Approval Status Route of Administration First Approved / Isolated Year Connections
Treats
Source Apadamtase alfa (Wikipedia)
Sources
1. Apadamtase alfa (Wikipedia)
Lead section
Apadamtase alfa was approved for medical use in the United States in November 2023, and in the European Union in August 2024.
Lead section [route-of-administration]
It is given by injection into a vein.
Treats: Thrombotic thrombocytopenic purpura, Lead section [treats]
used for the treatment of thrombotic thrombocytopenic purpura
View the SourceReader Challenges (0)
No disputes yet. Spotted an error or a better source? Open the first one.
Sign in to dispute this or suggest a correction.